(Q33245149)

English

The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines (English)

1 reference

Europe PubMed Central

24 July 2017

object named as

Filip Lardon

8

0 references

author name string

Bea Pauwels

1

1 reference

Europe PubMed Central

24 July 2017

Annelies E C Korst

2

1 reference

Europe PubMed Central

24 July 2017

Greet G O Pattyn

3

1 reference

Europe PubMed Central

24 July 2017

Hilde A J Lambrechts

4

1 reference

Europe PubMed Central

24 July 2017

Juliette A E Kamphuis

5

1 reference

Europe PubMed Central

24 July 2017

Christel M J De Pooter

6

1 reference

Europe PubMed Central

24 July 2017

Godefridus J Peters

7

1 reference

Europe PubMed Central

24 July 2017

Jan B Vermorken

9

1 reference

Europe PubMed Central

24 July 2017

language of work or name

0 references

publication date

30 May 2006

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

6

1 reference

Europe PubMed Central

24 July 2017

142

1 reference

Europe PubMed Central

24 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

30 May 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1471-2407-6-142

0 references

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Mismatch repair proficiency is not required for radioenhancement by gemcitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Preclinical, pharmacologic, and phase I studies of gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Preclinical combination therapy with gemcitabine and mechanisms of resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Gemcitabine: preclinical pharmacology and mechanisms of action.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

21 June 2018

The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Chemoradiation with gemcitabine for cervical cancer in patients with renal failure

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Selective targeting of homologous DNA recombination repair by gemcitabine

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

Radiation enhancement by gemcitabine-mediated cell cycle modulations

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-142

21 January 2018

The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

31 October 2018

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

31 October 2018

End-joining deficiency and radiosensitization induced by gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

31 October 2018

The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1513392

31 October 2018

Enhancement of tumor radioresponse in vivo by gemcitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiosensitization of human tumor cells by gemcitabine in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximizing therapeutic gain with gemcitabine and fractionated radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimization of the sulforhodamine B colorimetric assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16734894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-6-142

1 reference

Europe PubMed Central

24 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33245149&oldid=1802388676"